Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01145196 · ClinicalTrials.gov registry record
Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene
A clinical trial of Retinal Disease and Genotype, sponsored by National Eye Institute (NEI).
- Recruiting
- Registry status
- 320
- Enrollment target
- 1
- Study location
NCT01145196 is a study of Retinal Disease and Genotype that is actively recruiting participants, run by National Eye Institute (NEI). The registered enrollment target is 320 participants, below the 1,224-participant average among 19 other Retinal Disease trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01145196, a study of Retinal Disease and Genotype, is actively recruiting participants, sponsored by National Eye Institute (NEI).
- RECRUITING
- Registry status
- 320 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- Plaquenil (hydroxychloroquine) is an anti-inflammatory drug that is used to treat some autoimmune diseases such as lupus and rheumatoid arthritis. This drug can damage the retina by causing a condition called plaquenil-induced retinal toxicity, which may lead to vision loss. However, most people taking plaquenil do not develop this problem. Researchers are interested in studying whether differences in a person s genes explain why some people develop plaquenil-induced retinal toxicity while others do not. Objectives: \- To investigate possible correlations between certain genes or genetic mutations and plaquenil-induced retinal toxicity. Eligibility: * Individuals at least 18 years of age who have previously used plaquenil. * Both individuals who have and have not developed plaquenil-induced retinal toxicity will be eligible for this study. Design: * The study requires one or two visits to the National Eye Institute or an outpatient study clinic over a maximum 2-year period. * Participants will provide a personal and family medical history, and will have a full eye examination. * Participants will also provide blood samples for testing. * No treatment will be provided as part of this protocol.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2010-08-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01145196
The ClinicalTrials.gov registry entry for NCT01145196 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,224-participant average among 19 other Retinal Disease trials with a reported enrollment target (74% lower). The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Retinal Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01145196 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01145196 about?
NCT01145196 is a clinical study titled "Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene". Background: \- Plaquenil (hydroxychloroquine) is an anti-inflammatory drug that is used to treat some autoimmune diseases such as lupus and rheumatoid arthritis. This drug can damage the retina by causing a condition called plaquenil-induced retinal toxicity, which may lead to vision loss. However,...
What is the current status of trial NCT01145196?
This trial is currently recruiting. The enrollment target is 320 participants. The study started on 2010-08-23.
What conditions does trial NCT01145196 study?
This clinical trial studies the following conditions: Retinal Disease, Genotype.
Who is sponsoring clinical trial NCT01145196?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01145196 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
RECRUITING · Phase 3
-
COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Inherited Retinal Disease
RECRUITING · NA
-
P200TxE Diseased Eye Image Collection
RECRUITING · NA
-
Data Gathering for A10900
RECRUITING
-
Inherited Retinal Degenerative Disease Registry
RECRUITING
-
Cell Collection to Study Eye Diseases
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.